SE521031C2 - Nya specifika inhibitorer av akut och kronisk inflammation - Google Patents
Nya specifika inhibitorer av akut och kronisk inflammationInfo
- Publication number
- SE521031C2 SE521031C2 SE9901615A SE9901615A SE521031C2 SE 521031 C2 SE521031 C2 SE 521031C2 SE 9901615 A SE9901615 A SE 9901615A SE 9901615 A SE9901615 A SE 9901615A SE 521031 C2 SE521031 C2 SE 521031C2
- Authority
- SE
- Sweden
- Prior art keywords
- cells
- adhesion
- acute
- selectin
- thiouridine
- Prior art date
Links
- 208000038016 acute inflammation Diseases 0.000 title abstract 3
- 230000006022 acute inflammation Effects 0.000 title abstract 3
- 208000037976 chronic inflammation Diseases 0.000 title abstract 3
- 230000006020 chronic inflammation Effects 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims abstract description 22
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims abstract description 11
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940045145 uridine Drugs 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000023597 hemostasis Effects 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 20
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 claims description 15
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 claims description 12
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 claims description 10
- 230000037396 body weight Effects 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 23
- 239000000126 substance Substances 0.000 description 15
- 102000015689 E-Selectin Human genes 0.000 description 14
- 108010024212 E-Selectin Proteins 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 102000003800 Selectins Human genes 0.000 description 7
- 108090000184 Selectins Proteins 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901615A SE521031C2 (sv) | 1999-05-05 | 1999-05-05 | Nya specifika inhibitorer av akut och kronisk inflammation |
| CA002373052A CA2373052A1 (en) | 1999-05-05 | 2000-05-02 | Novel, specific inhibitors of acute and chronic inflammation |
| EP07102064A EP1790348A3 (de) | 1999-05-05 | 2000-05-02 | Verwendung von Uridin zur Behandlung von Entzündungen und/oder Hämostasis |
| AU52592/00A AU776520B2 (en) | 1999-05-05 | 2000-05-02 | Novel, specific inhibitors of acute and chronic inflammation |
| DE60035583T DE60035583T2 (de) | 1999-05-05 | 2000-05-02 | Verwendung von 4-Thiouridin oder Isomaltitol zur Behandlung von Entzündungen und/oder Hämostasis |
| JP2000616785A JP2002544165A (ja) | 1999-05-05 | 2000-05-02 | 急性及び慢性炎症の新規な特異的抑制剤 |
| EP00937418A EP1181021B1 (de) | 1999-05-05 | 2000-05-02 | Verwendung von 4-Thiouridin oder Isomaltitol zur Behandlung von Entzündungen und/oder Hämostasis |
| AT00937418T ATE367164T1 (de) | 1999-05-05 | 2000-05-02 | Verwendung von 4-thiouridin oder isomaltitol zur behandlung von entzündungen und/oder hämostasis |
| BR0010283-0A BR0010283A (pt) | 1999-05-05 | 2000-05-02 | Novos inibidores especìficos de inflamação aguda e crÈnica |
| PCT/SE2000/000827 WO2000067759A1 (en) | 1999-05-05 | 2000-05-02 | Novel, specific inhibitors of acute and chronic inflammation |
| US09/986,522 US20020061863A1 (en) | 1999-05-05 | 2001-11-02 | Novel, specific inhibitors of acute and chronic inflammation |
| US10/994,663 US7687476B2 (en) | 1999-05-05 | 2004-11-22 | Specific inhibitors of acute and chronic inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9901615A SE521031C2 (sv) | 1999-05-05 | 1999-05-05 | Nya specifika inhibitorer av akut och kronisk inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9901615D0 SE9901615D0 (sv) | 1999-05-05 |
| SE9901615L SE9901615L (sv) | 2000-12-15 |
| SE521031C2 true SE521031C2 (sv) | 2003-09-23 |
Family
ID=20415466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9901615A SE521031C2 (sv) | 1999-05-05 | 1999-05-05 | Nya specifika inhibitorer av akut och kronisk inflammation |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20020061863A1 (de) |
| EP (2) | EP1790348A3 (de) |
| JP (1) | JP2002544165A (de) |
| AT (1) | ATE367164T1 (de) |
| AU (1) | AU776520B2 (de) |
| BR (1) | BR0010283A (de) |
| CA (1) | CA2373052A1 (de) |
| DE (1) | DE60035583T2 (de) |
| SE (1) | SE521031C2 (de) |
| WO (1) | WO2000067759A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE529064C2 (sv) * | 2005-01-03 | 2007-04-24 | Selectica Pharmaceuticals Ab | Topiska kompositioner |
| AU2008324033B2 (en) * | 2007-11-05 | 2014-01-09 | Humanitarian Scientific Llc | Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias |
| WO2019112383A1 (ko) * | 2017-12-08 | 2019-06-13 | 윤주석 | 금속 미네랄 디아미네이트 및 이의 제조방법 |
| CN114469981A (zh) * | 2021-12-16 | 2022-05-13 | 中国科学院动物研究所 | 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2217628C2 (de) * | 1972-04-12 | 1974-06-06 | Sueddeutsche Zucker Ag | Verfahren zur Herstellung von alpha-D-Glucopyranosido eckige Klammer auf 1-6 eckige Klammer zu sorbit (Isomaltit) |
| DE2307251C2 (de) * | 1973-02-14 | 1984-03-29 | Süddeutsche Zucker AG, 6800 Mannheim | Arzneimittel zur Behandlung von chronischer Obstipation und Leberschäden |
| HK1005740A1 (en) | 1987-10-28 | 1999-01-22 | Wellstat Therapeutics Corporation | Acylated uridine and cytidine and uses thereof |
| US5691320A (en) * | 1987-10-28 | 1997-11-25 | Pro-Neuron, Inc. | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| US6329350B1 (en) * | 1987-10-28 | 2001-12-11 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| US5607925A (en) * | 1988-11-15 | 1997-03-04 | Merrell Pharmaceuticals Inc. | Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides |
| MX9203459A (es) * | 1988-11-15 | 1992-08-01 | Merrell Pharma Inc | Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina. |
| JP2529605B2 (ja) | 1989-10-23 | 1996-08-28 | 株式会社大塚製薬工場 | 免疫賦活剤 |
| IT1241984B (it) * | 1990-06-13 | 1994-02-02 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete |
| DK0600930T3 (da) * | 1991-08-02 | 2002-12-02 | Denise L Faustman | Diagnose og behandling af autoimmune sygdomme |
| US5229415A (en) | 1992-03-24 | 1993-07-20 | Merck & Co., Inc. | Alkylthio alkyl avermectins are active antiparasitic agents |
| US5646182A (en) * | 1992-06-15 | 1997-07-08 | Burzynski; Stanislaw R. | Methods for treating autoimmune diseases |
| CA2588495C (en) * | 1992-12-08 | 2009-11-17 | Wellstat Therapeutics Corporation | The utility of uridine nucleosides in the treatment of cachexia |
| WO1994026280A1 (fr) * | 1993-05-19 | 1994-11-24 | Korea Green Cross Corporation | Remede contre l'arthrite contenant de l'uridine comme ingredient actif |
| US5567689A (en) * | 1993-08-13 | 1996-10-22 | The Uab Research Foundation | Methods for increasing uridine levels with L-nucleosides |
| US5852000A (en) * | 1993-08-25 | 1998-12-22 | Otsuka Pharmaceutical Factory, Inc. | Cardiac rehabilitation agent |
| WO1996001115A1 (en) * | 1994-07-01 | 1996-01-18 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| US5753625A (en) * | 1995-05-12 | 1998-05-19 | Sangstat Medical Corporation | Treatment for inhibiting the progression of autoimmune disease |
| US5962459A (en) * | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| US5789391A (en) * | 1996-07-03 | 1998-08-04 | Inspire Pharmaceuticals, Inc. | Method of treating sinusitis with uridine triphosphates and related compounds |
| SE9701219D0 (sv) * | 1997-04-04 | 1997-04-04 | Astra Pharma Prod | New compounds |
| EP1019725A2 (de) * | 1997-07-22 | 2000-07-19 | Novimmune Sa | Verfahren zur diagnose und therapie von autoimmunen krankheiten, wie insulin abhängiges diabetes mellitus mitels retorviraler superantigene |
| US20020006913A1 (en) * | 1997-11-04 | 2002-01-17 | Von Borstel Reid W. | Antimutagenic compositions for treatment and prevention of photodamage to skin |
| US6673606B1 (en) * | 2000-04-12 | 2004-01-06 | The Children's Hospital Of Philadelphia | Therapeutic uses for mesenchymal stromal cells |
-
1999
- 1999-05-05 SE SE9901615A patent/SE521031C2/sv not_active IP Right Cessation
-
2000
- 2000-05-02 WO PCT/SE2000/000827 patent/WO2000067759A1/en not_active Ceased
- 2000-05-02 EP EP07102064A patent/EP1790348A3/de not_active Withdrawn
- 2000-05-02 AU AU52592/00A patent/AU776520B2/en not_active Ceased
- 2000-05-02 AT AT00937418T patent/ATE367164T1/de not_active IP Right Cessation
- 2000-05-02 CA CA002373052A patent/CA2373052A1/en not_active Abandoned
- 2000-05-02 DE DE60035583T patent/DE60035583T2/de not_active Expired - Fee Related
- 2000-05-02 BR BR0010283-0A patent/BR0010283A/pt not_active Application Discontinuation
- 2000-05-02 JP JP2000616785A patent/JP2002544165A/ja active Pending
- 2000-05-02 EP EP00937418A patent/EP1181021B1/de not_active Expired - Lifetime
-
2001
- 2001-11-02 US US09/986,522 patent/US20020061863A1/en not_active Abandoned
-
2004
- 2004-11-22 US US10/994,663 patent/US7687476B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000067759A1 (en) | 2000-11-16 |
| EP1790348A2 (de) | 2007-05-30 |
| DE60035583D1 (de) | 2007-08-30 |
| US20050090467A1 (en) | 2005-04-28 |
| AU776520B2 (en) | 2004-09-16 |
| SE9901615L (sv) | 2000-12-15 |
| EP1181021A1 (de) | 2002-02-27 |
| US20020061863A1 (en) | 2002-05-23 |
| US7687476B2 (en) | 2010-03-30 |
| BR0010283A (pt) | 2003-07-29 |
| SE9901615D0 (sv) | 1999-05-05 |
| DE60035583T2 (de) | 2008-04-17 |
| EP1790348A3 (de) | 2007-06-13 |
| ATE367164T1 (de) | 2007-08-15 |
| AU5259200A (en) | 2000-11-21 |
| EP1181021B1 (de) | 2007-07-18 |
| CA2373052A1 (en) | 2000-11-16 |
| JP2002544165A (ja) | 2002-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaspers et al. | In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood | |
| Juliusson et al. | Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. | |
| Neftel et al. | Inhibition of granulopoiesis in vivo and in vitro by β-lactam antibiotics | |
| Serebro et al. | Inhibition of cholera toxin action in the rabbit by cycloheximide | |
| Arzt et al. | Immunomodulation by indoleamines: serotonin and melatonin action on DNA and interferon-γ synthesis by human peripheral blood mononuclear cells | |
| Baccarini et al. | In vitro natural cell-mediated cytotoxicity against Candida albicans: macrophage precursors as effector cells. | |
| Lin et al. | Effects of amphotericin B on macrophages and their precursor cells | |
| Burstein et al. | Megakaryocytopoiesis in culture: Modulation by cholinergic mechanisms | |
| SE513429C2 (sv) | Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer | |
| Minasian et al. | Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma | |
| Rosenthal et al. | Serum amyloid A: evidence for its origin in polymorphonuclear leukocytes | |
| SE521031C2 (sv) | Nya specifika inhibitorer av akut och kronisk inflammation | |
| Beutler et al. | The regulation of iron absorption I. a search for humoral factors | |
| Stryckmans et al. | Mode of action of chemotherapy in vivo on human acute leukemia—II. Vincristine | |
| Lucas et al. | Cytotoxic Activity of Lymphocytes: III. Standardization of Measurement of Cell-Mediated Lysis | |
| EP3609471B1 (de) | Formulierung von (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphon mit erhöhter stabilität und bioverfügbarkeit | |
| Berenbaum | The immunosuppressive effects of 5-fluorocytosine and 5-fluorouracil | |
| CN114432316A (zh) | 含全反式维甲酸和帕博西尼的药物组合物及其用途 | |
| CN117122606A (zh) | 淫羊藿次苷i在治疗或预防微卫星稳定型实体瘤中的应用及包含其的药盒 | |
| Goldstone et al. | A case of small-cell Sézary's syndrome with null-cell features. | |
| Herve et al. | Attempts to Eliminate Residual Acute Myeloid Leukemia from Autologous Bone Marrow Grafts Through In Vitro Chemotherapy—A Review— | |
| Bargetzi et al. | Recombinant human interleukin‐3 in refractory severe aplastic anaemia: a phase I/II trial | |
| CN119326763B (zh) | 7H-吲哚[2,3-j]菲啶-7,13(8H)-二酮用作JAK2抑制剂以及用于制备缓解、治疗胰腺癌的药物中的应用 | |
| Smith et al. | In vitro sensitivity of normal granulocytic and lymphoma colonies to vinca alkaloids | |
| Shau et al. | Regulation of human natural killing by levamisole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |